Lyra Therapeutics, Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD
0.0944
-0.0106 (-10.10%)
May 8, 2025, 4:00 PM EDT - Market closed
-10.10%
Market Cap 6.26M
Revenue (ttm) 1.19M
Net Income (ttm) -79.53M
Shares Out 66.27M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,377,483
Open 0.0991
Previous Close 0.1050
Day's Range 0.0926 - 0.0991
52-Week Range 0.0820 - 0.4190
Beta 0.05
Analysts Hold
Price Target 1.25 (+1,224.15%)
Earnings Date May 6, 2025

About LYRA

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients wh... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2020
Employees 30
Stock Exchange NASDAQ
Ticker Symbol LYRA
Full Company Profile

Financial Performance

In 2024, Lyra Therapeutics's revenue was $1.53 million, a decrease of -1.54% compared to the previous year's $1.56 million. Losses were -$93.44 million, 49.1% more than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LYRA stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 1,224.15% from the latest price.

Price Target
$1.25
(1,224.15% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory s...

1 day ago - GlobeNewsWire

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic...

2 days ago - GlobeNewsWire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.  (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory...

2 months ago - GlobeNewsWire

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --   Lyra Therapeutics, Inc.  (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammator...

6 months ago - GlobeNewsWire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company deve...

7 months ago - GlobeNewsWire

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory ...

7 months ago - GlobeNewsWire

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned –

9 months ago - GlobeNewsWire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in...

1 year ago - GlobeNewsWire

3 'Buy-Rated' Biotech Stocks Under $10

Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presente...

Other symbols: ADMAGERN
1 year ago - Seeking Alpha

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal impl...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: L...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhino...

1 year ago - GlobeNewsWire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chroni...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...

1 year ago - GlobeNewsWire

Lyra Therapeutics: Hold For Phase 3 Topline

Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 t...

1 year ago - Seeking Alpha

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatments. The company maintains a stable balance sheet ...

1 year ago - Seeking Alpha

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks

1 year ago - GlobeNewsWire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory th...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Re...

1 year ago - GlobeNewsWire

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...

1 year ago - GlobeNewsWire

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Lyra is a small company founded by Bob Langer of MIT. The company has solid Phase 2 data in chronic rhinosinusitis, and Phase 3 data drop is early next year. Lyra has a decent cash runway and looks in...

2 years ago - Seeking Alpha

Lyra Therapeutics to Present at Jefferies Healthcare Conference

WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...

2 years ago - GlobeNewsWire